Toronto – Toronto Public Health (TPH) is hosting pop-up vaccination clinics this summer across Toronto in partnership with many festivals and special events. This is part of Team Toronto’s ongoing efforts to continue to bring COVID-19 vaccination opportunities to places residents live, work and play. The first summer vaccination clinics can be found at: Toronto Beaches RibFest at Woodbine Beach …
Canada strengthens Canada’s clinical trials environment
Clinical Trials Fund will lead to improved treatments for all Canadians Ottawa – Clinical trials are essential scientific studies that evaluate the safety, effectiveness, and outcomes of health interventions such as vaccines and treatments used across Canada to protect Canadians from diseases. The Government of Canada is working to reinforce the clinical trials environment so that we can improve health …
$200m invested to enhance Covid vaccine delivery, demand and production
Ottawa – Immunizing a critical mass of the world’s population is crucial in getting the COVID-19 pandemic under control. Many countries in the Global South, however, continue to encounter challenges in getting vaccines into arms, particularly in remote communities. Strengthening all levels of health care—local, regional and national—is critical to supporting vaccine distribution, as is promoting vaccine confidence and uptake. Harjit S. Sajjan, Minister of International …
Health Canada on Moderna’s Spikevax Covid-19 vaccine
Ottawa – The vaccine is approved for people who are 6 years of age and older. Its safety and effectiveness in people younger than 6 years of age have not yet been established. Effectiveness Clinical trials showed that beginning 2 weeks after the second dose, the Moderna Spikevax® COVID vaccine was: 94.1% effective in protecting trial participants aged 18 and above …
All about Vaxzevria (ChAdOx1-S)
London – Vaxzevria is a vaccine for preventing coronavirus disease 2019 (COVID-19) in people aged 18 years and older. Vaxzevria is made up of another virus (of the adenovirus family) that has been modified to contain the gene for making a protein from SARS-CoV-2, the virus that causes COVID-19. Vaxzevria does not contain the virus itself and cannot cause COVID-19.
Toronto hosts monkeypox community vaccination clinic
Toronto – Representatives from Toronto Public Health (TPH) and The 519 explained the community-based approach to administer the monkeypox vaccine to high-risk groups at Barbara Hall Park, beside the playground, located at the rear of The 519, 519 Church St. The 519 hosted one of two Saturday monkeypox vaccination clinics from 10 a.m. to 4 p.m. The other clinic took …
FDA gives nod for Covid vaccines for kids under 5
Washington – The US Food and Drug Administration has authorised two Covid-19 vaccines for children aged 5 and under. It authorised Pfizer-BioNTech’s, vaccine for children aged 6 months to 4 years, and Moderna’s shot for those 6 months to 17 years. Pfizer’s is already authorised for those over the age of 5. While many parents in the United States are …
FDA, pill alopecia treatment
Washington- The US Food and Drug Administration has recently approved baricitinib as the first oral tablet for treating severe alopecia areata, an autoimmune disorder. The disease affects over 300,000 people in the United States every year and causes temporary or permanent patchy hair loss. The disease came under the scanner after Hollywood actress Jada Pinkett Smith and congresswoman Ayanna Pressley …
WHO to share vaccines to stop monkeypox
LONDON (AP) The World Health Organization said it’s creating a new vaccine-sharing mechanism to stop the outbreak of monkeypox in more than 30 countries beyond Africa. The move could result in the UN health agency distributing scarce vaccine doses to rich countries that can otherwise afford them. To some health experts, the initiative potentially misses the opportunity to control monkeypox …
Amylyx gets first approval in Canada
Ottawa (Reuters) – Canada has approved Amylyx Pharmaceuticals’ treatment for amyotrophic lateral sclerosis (ALS), a neurodegenerative disease, the drugmaker said, the first such approval for the oral drug. The decision came with certain conditions, including the release of data from its global late-stage study of about 600 patients, which is expected in 2024, as well as additional studies. The approval for …